Additionally, the distinction between ongoing HRD and historic HRD needs to be properly assessed in tumours; historic HRD may leave the scars on the genome that indicate that the tumour is HR‐deficient, but the tumour may have reinstated HR through mechanisms such as PTEN mutation, or compensating mutations up‐ or down‐stream of the core HR pathway genes [69]. The gene discussed is PTEN; the disease is neoplasm.